Rory Sutherland Rory Sutherland

Aspirin should be reassuringly expensive

Effective ­placebos have to be rare, costly, foul-tasting or ideally all three

issue 30 July 2016

Last year, those rationalist killjoys at the Australian Competition and Consumer Commission prosecuted Reckitt Benckiser over four products: Nurofen Migraine Pain, Nurofen Tension Headache, Nurofen Period Pain and Nurofen Back Pain. Their gripe was that ‘each product claimed to target a specific pain, when in fact it was found that they all contained the same amount of the same active ingredient, ibuprofen lysine.’ These variants were often sold at a higher price than the basic brand, despite being pharmacologically identical.

I am sure the ACCC have their chemistry right; their psychology, however, is wrong. For me, Nurofen didn’t go far enough. I want to see even more specific variants: ‘I Can’t Find My Car Keys Nurofen’, perhaps, or ‘Nurofen for People whose Neighbours Like Reggae’. Again, these need contain no additional ingredients: the only distinguishing feature would be the packaging and the promise.

I’m not being entirely frivolous here. Research into the placebo effect shows that branded analgesics are more effective.

Comments

Join the debate for just $5 for 3 months

Be part of the conversation with other Spectator readers by getting your first three months for $5.

Already a subscriber? Log in